 |
274 Diseases |  |
1060 Trials |
|
1060 Trials |  |
12189 News |  |
| «12...7891011121314151617...178179» |
- TARGETING THE CD44 VARIANT ISOFORMS USING A NOVEL CDC-LIKE PROTEIN KINASE INHIBITOR TO IMPROVE THE EFFICACY OF STANDARD-OF-CARE THERAPY FOR PANCREATIC DUCTAL ADENOCARCINOMA (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_2924;
PDAC monolayers generated from the PDOs were treated with SOC Gemcitabine/Nab-Paclitaxel or FOLFIRINOX alone or in combination with CLK inhibitor (CLKinh) pre-treatment... Inhibition of the alternative splicing of CD44 using CLK kinase inhibitor might offer a therapeutic strategy to improve the efficacy of SOC in PDAC patients.
- | Avastin (bevacizumab) / Roche, iparomlimab/tuvonralimab (PSB205) / Sound Biologics, Qilu Pharma
New P2 trial, Metastases: First-line Regimen With QL1706 Plus Chemo (clinicaltrials.gov) - Mar 14, 2024
P2, N=50, Not yet recruiting, Sponsor: Fudan University
- Prolia (denosumab) / Amgen
Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer - Time to Event analysis from the GeparX 2 (Hamburg Hall) - Mar 14, 2024 - Abstract #ESMOBC2024ESMO_BC_236;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead, Tecentriq (atezolizumab) / Roche
Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: A Phase Ib/II study of multiple treatment (tx) combinations in pts with locally advanced/metastatic BC (LA/mBC) (Berlin Hall) - Mar 14, 2024 - Abstract #ESMOBC2024ESMO_BC_171;
P1/2
PFS data were immature but showed a trend towards benefit with atezo + SG. Safety of atezo + SG was consistent with the profiles of the individual drugs, with no new safety signals seen.
- | Halaven (eribulin mesylate) / Eisai
Retrospective data, Journal, Metastases: Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study. (Pubmed Central) - Mar 14, 2024
For the salvage treatment of advanced TNBC, treatment with eribulin produced longer median PFS and OS than other chemotherapy regimens, with a well-tolerated safety profile. Therefore, further investigation of eribulin-based treatment in larger randomized trials for patients with advanced TNBC is warranted.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Journal, Metastases: Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma. (Pubmed Central) - Mar 13, 2024
Camrelizumab plus albumin paclitaxel and carboplatin were found to be safe and effective in the neoadjuvant treatment of borderline resectable or unresectable locally advanced esophageal cancer. It was observed to improve the rate of curative resection without increasing perioperative complications.
- || volrustomig (MEDI5752) / AstraZeneca
Enrollment closed, Metastases: FTIH: A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Mar 13, 2024
P1, N=401, Active, not recruiting, Sponsor: MedImmune LLC
It was observed to improve the rate of curative resection without increasing perioperative complications. Recruiting --> Active, not recruiting
- | Trial primary completion date: Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer (clinicaltrials.gov) - Mar 12, 2024
P1/2, N=120, Recruiting, Sponsor: Flemming Forsberg
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2024 --> Dec 2024
- | Keytruda (pembrolizumab) / Merck (MSD), MK-0482 / Merck (MSD)
Phase classification, Combination therapy, Monotherapy, Metastases: A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov) - Mar 12, 2024
P1, N=230, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial primary completion date: Jun 2024 --> Dec 2024 Phase classification: P1b --> P1
- | Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Metastases: CCTG PA.7: Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Mar 12, 2024
P2, N=180, Active, not recruiting, Sponsor: Canadian Cancer Trials Group
Phase classification: P1b --> P1 Trial completion date: Dec 2023 --> Dec 2024
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS
Impact of Neoadjuvant Chemo-Immunotherapy on Intra and Post Operative Outcomes in Patients with Bladder Cancer Treated with Radical Cystectomy and Pelvic Lymph Node Dissection: Prospective Surgical Assessment from the NURE-Combo Trial (304B) - Mar 12, 2024 - Abstract #AUA2024AUA_2760;
P2
We report intra and perioperative outcomes after RC+Pelvic Lymph Node Dissection (PLND) in pts with MIBC enrolled in a phase 2 trial of neoadjuvant Nivolumab (NIVO) + Nab-paclitaxel (ABX) (NCT04876313)...The secondary endpoint was to compare perioperative outcomes of our cohort to 105 pts with MIBC who received 3 cycles of neoadjuvant Pembrolizumab (PEMBRO) 200 mg Q3W followed RC+PLND, inside the PURE01 trial (NCT02736266)... Our data represent the first prospective evidence supporting the surgical safety of RC+PLND in pts with MIBC who received neoadjuvant combination of chemo-immunotherapy with NIVO+ABX.
- Opdivo (nivolumab) / Ono Pharma, BMS
Efficacy and safety of the combination of Cisplatin plus Nab-paclitaxel and Nivolumab with radiotherapy after maximal tumor resection in non-metastatic muscle invasive Bladder Cancer (CNN-BC trial). (304B) - Mar 12, 2024 - Abstract #AUA2024AUA_2747;
P2
Our data represent the first prospective evidence supporting the surgical safety of RC+PLND in pts with MIBC who received neoadjuvant combination of chemo-immunotherapy with NIVO+ABX. On going.
- Opdivo (nivolumab) / Ono Pharma, BMS
First results of NURE-Combo: a phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC) (304A) - Mar 12, 2024 - Abstract #AUA2024AUA_2462;
P2
These results could expand the opportunities of chemotherapy combinations beyond cisplatin. Results also strengthen the role of clinical complete response to envision organ-sparing approaches.
- | Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial, Metastases: Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Mar 12, 2024
P2, N=25, Recruiting, Sponsor: Tongji University
- |||||| erfonrilimab (KN046) / Alphamab
Enrollment open, Metastases: ENREACH-PDAC-01: KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma. (clinicaltrials.gov) - Mar 12, 2024
P3, N=408, Recruiting, Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Results also strengthen the role of clinical complete response to envision organ-sparing approaches. Active, not recruiting --> Recruiting
- albumin-bound paclitaxel / Generic mfg.
Utilizing nature tropism of a novel nanomaterial towards cancer stem cells | Poster Board #M12 (In-person; Poster Board #M12; Studio 3 - 10 (New Orleans Marriott)) - Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_11502;
Active, not recruiting --> Recruiting When chemotherapeutic agent, paclitaxel (PTX), was encapsulated in the P 2 NPs (PTX-P 2 ), the delivery efficiency of PTX to the MDA-MB-231 cells was significantly improved when compared with PTX-P 1 and Abraxane
- Synthesis of a daucane-type natural product with antiausterity activity against the PANC-1 pancreatic cancer cells (Virtual; Virtual Session (Virtual Only)) - Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_7940;
Current standard-of-care first-line chemotherapeutic agents including FOLFIRINOX and gemcitabine/nab-paclitaxel regimens only offered limited increase in median survival rates, and development of new treatment strategies is necessary...Upon completion of the syntheses, mode-of-action studies of ferutinin will be conducted. Analogs of the target compound will be designed and synthesized, and structure-activity relationships (SARs) will be established to guide future development of antiausterity agents to treat human pancreatic cancer.
- Combination drug delivery using mesoporous silica nanoparticles for targeted therapy in pancreatic cancer | Poster Board #1219 (In-person; Poster Board #1219; Hall C (Ernest N. Morial Convention Center)) - Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_1437;
Current standards of care for PDAC involve the combination of two drugs (Gemcitabine+nab-paclitaxel) or more (FOLFIRINOX); however, combinations produce dramatic toxic effects on patients...In this study, we synthesized an MSN platform chemically loaded with cisplatin (cisPt) to internal pores and conjugated with gemcitabine (Gem) to the external surface of MSNs (Gem-cisPt-MSNs)...In addition, this synergistic effect is drug ratio-dependent. We envision that the use of nanoparticles will help to alleviate some of the main issues related to the treatment of PDAC; in particular, the drug resistance against current standard of care.
- | adebrelimab (SHR-1316) / Jiangsu Hengrui Pharma, Ameile (aumolertinib) / Jiangsu Hansoh Pharma
New P2 trial, IO biomarker: NEOVADE: Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC (clinicaltrials.gov) - Mar 11, 2024
P2, N=32, Not yet recruiting, Sponsor: Guangdong Provincial People's Hospital
- | albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Trial completion date, Trial primary completion date, Surgery, Metastases: A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) - Mar 11, 2024
P1/2, N=30, Active, not recruiting, Sponsor: University Health Network, Toronto
We envision that the use of nanoparticles will help to alleviate some of the main issues related to the treatment of PDAC; in particular, the drug resistance against current standard of care. Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
P2 data, Journal: Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A phase II single-arm study. (Pubmed Central) - Mar 8, 2024
This dual HER2-blockade with sequential polychemotherapy showed promising activity with rapid tumor regression in HER2-positive BC. Importantly, this regimen showed an acceptable safety profile, especially a low risk of cardiac events, suggesting it as an attractive treatment approach with a favorable risk-benefit balance.
- | albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Journal: Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness. (Pubmed Central) - Mar 8, 2024
Importantly, this regimen showed an acceptable safety profile, especially a low risk of cardiac events, suggesting it as an attractive treatment approach with a favorable risk-benefit balance. FGFR1 drives chemoresistance and tumor aggressiveness, which FGFRi can reverse.
- irinotecan / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Predictors of Overall Survival (OS) and Time to Next Treatment (TTNT) in Real-World Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Patients Who Received First-Line (1L) Folfirinox (FFX) or Gemcitabine + Nab-paclitaxel (GnP) () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_568;
1L GnP was associated with lower OS and marginally lower TTNT relative to FFX. Abnormal SA, ALP, and higher ECOG score predicted inferior outcomes.
- Keytruda (pembrolizumab) / Merck (MSD)
Healthcare Cost and Healthcare Resource Utilization (HCRU) Among First-Line (1L) Treated Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC): Analysis of Seer-Medicare Linked Claims in the US () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_471;
6-month post NSCLC diagnosis) patients who completed ?4 induction cycles with 1L pembrolizumab combination-therapy with cisplatin/carboplatin plus pemetrexed (Cohort 1) or paclitaxel/nab-paclitaxel (Cohort 2); and initiated the 5 th treatment cycle (i.e., index date) were included. First-line treated patients with mNSCLC who initiated a 5 th cycle bear substantial economic burden.
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
P2 data, Journal, Combination therapy, Metastases: Efficacy of nab?paclitaxel vs. Gemcitabine in combination with S?1 for advanced pancreatic cancer: A multicenter phase II randomized trial. (Pubmed Central) - Mar 7, 2024
In particular, promising survival benefits were observed in the subsets of patients with KRAS gene mutations and high CRP levels, which is encouraging and warrants further investigation. This trial was retrospectively registered as ChiCTR1900024588 on July 18, 2019.
- | Opdivo (nivolumab) / BMS
Enrollment open, Trial completion date, Trial primary completion date, IO biomarker, Metastases: CNN-BC: Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer (clinicaltrials.gov) - Mar 7, 2024
P2, N=32, Recruiting, Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
This trial was retrospectively registered as ChiCTR1900024588 on July 18, 2019. Not yet recruiting --> Recruiting | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
- | adebrelimab (SHR-1316) / Jiangsu Hengrui Pharma
New P2 trial, Combination therapy: Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations (clinicaltrials.gov) - Mar 7, 2024
P2, N=36, Not yet recruiting, Sponsor: Liaoning Tumor Hospital & Institute
- | cisplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Trial completion date, Trial primary completion date, Combination therapy: Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases (clinicaltrials.gov) - Mar 6, 2024
P1, N=12, Recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Dec 2023 --> Dec 2025 Trial completion date: Mar 2024 --> Oct 2028 | Trial primary completion date: Mar 2024 --> Oct 2028
- | albumin-bound paclitaxel / Generic mfg.
Journal: Efficacy of the traditional Chinese medicine, Buyang Huanwu Decoction, at preventing taxane-induced peripheral neuropathy in breast cancer patients: A prospective, randomized, controlled study. (Pubmed Central) - Mar 6, 2024
Trial completion date: Mar 2024 --> Oct 2028 | Trial primary completion date: Mar 2024 --> Oct 2028 Buyang Huanwu decoction (BYHWD) can effectively prevent TIPN and improve the quality of life in patients with breast cancer.
- || albumin-bound paclitaxel / Generic mfg.
Clinical data, Journal: Body composition measurements and clinical outcomes in patients with resectable pancreatic adenocarcinoma - analysis from SWOG S1505. (Pubmed Central) - Mar 6, 2024
P2
Visceral adipose tissue was associated with survival; however, there was no association between OS and sarcopenia or sarcopenic obesity. Further studies should evaluate these findings in more detail.
- | narmafotinib (AMP945) / Amplia Therap
Phase classification, Combination therapy: ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer (clinicaltrials.gov) - Mar 6, 2024
P1/2, N=62, Recruiting, Sponsor: Amplia Therapeutics Limited
Further studies should evaluate these findings in more detail. Phase classification: P1b/2a --> P1/2
- | paricalcitol / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Combination therapy, Metastases: Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer (clinicaltrials.gov) - Mar 6, 2024
P2, N=15, Completed, Sponsor: Cancer Trials Ireland
Phase classification: P1b/2a --> P1/2 Active, not recruiting --> Completed
- | albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date, Metastases: Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC) (clinicaltrials.gov) - Mar 6, 2024
P1/2, N=24, Recruiting, Sponsor: University of Maryland, Baltimore
Active, not recruiting --> Completed Trial primary completion date: Dec 2024 --> Dec 2025
- albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Tumor treating fields (TTFields) induce an anti-tumor immune response in a pancreatic cancer mouse model (Section 1) - Mar 5, 2024 - Abstract #AACR2024AACR_9469;
Our results suggest that TTFields may enhance the effects of standard-of-care chemotherapy for the treatment of PDAC. Furthermore, TTFields were shown to induce ICD and activate an antitumor immune response in PDAC, supporting future studies evaluating the efficacy of TTFields together with ICI in PDAC.
- albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
A dendritic cell targeted nanosystem to overcome immune suppression and enhance the efficacy of the standard of care for pancreatic cancer (Section 4) - Mar 5, 2024 - Abstract #AACR2024AACR_9446;
The NV proposed herein could induce a strong antigen-specific immune response against PDAC with restricted tumor growth while re-shaping PDAC immunosuppressive TME. Furthermore, our 3D patient-derived PDAC model allows us to assess the ability of our NV to generate specific immune responses in patients and to test other possible drug combinations predicting the clinical outcome.
- PLN-101095 / Pliant Therapeutics
Selective targeting of integrins ?V?8 and ?V?1 within the dynamic ecosystem of pancreatic cancer to improve the overall anti-tumor response (Room 5 - Upper Level - Convention Center) - Mar 5, 2024 - Abstract #AACR2024AACR_8804;
Finally, utilizing patient-derived models of metastatic PDA revealed that both PLN-104 and PLN-101095 significantly blocked tumour growth, improved the response to SoC chemotherapy Gemcitabine/Abraxane, and reduced metastatic spread to distant sites. In conclusion, these data provide scientific rationale for the design of future PLN-101095 and SoC chemotherapy as well as immunotherapy combinations in pancreatic cancer, with Phase I first-in-human oncology studies with PLN-101095 plus ICB already underway.
- MiR-345-5p attenuates pancreatic cancer metastasis through KLK7/E-Cad/ ?-Catenin/Rap1 axis (Section 17) - Mar 5, 2024 - Abstract #AACR2024AACR_8450;
MiR-345-5p overexpression negatively regulates PC proliferation and EMT by directly targeting KLK7/E-Cad/?-catenin/Rap1 axis. Restoring miR-345-5p with standard care therapies could be a promising strategy for improving survival in metastatic PC patients.
- celecoxib oral / Generic mfg.
Celecoxib and chloroquine enhance the antitumor effect of immune checkpoint blockade therapy, in a syngeneic mouse model for pancreatic cancer (Section 2) - Mar 5, 2024 - Abstract #AACR2024AACR_8220;
Overall, our data showed that celecoxib or the combination of celecoxib and chloroquine could substantially sensitize the mouse pancreatic tumors to the treatment of chemotherapy and ICIs. (This work was supported in part by the Seena Magowitz Foundation and the Purple Pansies)
- merestinib (LY2801653) / Eli Lilly
Enhancing nab-paclitaxel chemotherapy response in gastric cancer preclinical models through Inhibition of the HGF/c-Met pathway with merestinib (Section 26) - Mar 5, 2024 - Abstract #AACR2024AACR_8164;
Merestinib has strong antitumor activity in GAC, especially when administered with nab-paclitaxel, demonstrating a synergistic effect. These results provide compelling evidence for the potential clinical relevance of this combination therapy in improving the survival of GAC patients.
- AUM001 / AUM Biosci
Immunomodulatory and anticancer effects of cyclical gemcitabine/nab-paclitaxel with continuous dosing of tinodasertib (AUM001) in preclinical KPC model (Section 26) - Mar 5, 2024 - Abstract #AACR2024AACR_8157;
Additionally, the maintenance of AUM001 may enhance the decrease in pro-oncogenic protein expression and remodel the tumor immune microenvironment. In conclusion, continuous dosing of AUM001 following the cessation of chemotherapy could stabilize the tumor state, potentiating its application in clinical settings as maintenance therapy for PDAC.
- albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Disulfiram and its metal complexes reversed hypoxia induced stemness and synergized with first line drugs in primary patient derived pancreatic ductal adenocarcinoma cells (Section 24) - Mar 5, 2024 - Abstract #AACR2024AACR_8062;
Alb-CuDDC targets CSCs and overcomes resistance in PDAC, similar to free DSF-Cu. Alb-ZnDDC may have alternative mechanisms which are yet to be elucidated.
- BLX-3030 / Biolexis Therap
Development of a selective, oral ATP-competitive CDK9 inhibitor, BLX-3030, for treatment of pancreatic cancer (Section 27) - Mar 5, 2024 - Abstract #AACR2024AACR_7955;
Overall, the novel CDK9 inhibitor, BLX-3030, demonstrated potent activity in pancreatic cancer cell line models and presents a promising preclinical lead for pancreatic cancer. (This work was supported in part by Biolexis Therapeutics and the Seena Magowitz Foundation).
- Molecular characterization and drug sensitivity of a gastric FGFR2-TACC2 and a pancreatic KRAS p.G12C primary culture (Section 46) - Mar 5, 2024 - Abstract #AACR2024AACR_7816;
Primary cultures can be initiated from malignant pleural effusions and used for genetic characterization and drug sensitivity profiling. Primaries with specific alterations can be employed as preclinical models to test targeted therapies.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Lenvatinib as a potential treatment option for invasive mucinous lung adenocarcinoma (Section 46) - Mar 5, 2024 - Abstract #AACR2024AACR_7814;
P=N/A
We report two cases of metastatic RET fusion-negative mucinous lung adenocarcinoma, in which treatment with the multitargeted TKI Lenvatinib led to significant clinical improvement. Biological rationale to explain the effect of lenvatinib in invasive mucinous lung adenocarcinoma needs to be explored.
- albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Development of paclitaxel-loaded nanoparticles with high charge density (Section 20) - Mar 5, 2024 - Abstract #AACR2024AACR_7618;
In vitro cell viability assay (MTS) with and without TTFields is under exploration. With the successful formulation of PTX-loaded S-CAP NPs, co-loading PTX and gemcitabine can be explored to reduce the treatment burden of the patients.
- Analysis of the landscape of cancer-associated neurons (CANs) in diverse cancers through retrograde tracing and single cell molecular profiling (Section 10) - Mar 5, 2024 - Abstract #AACR2024AACR_7453;
In summary, our comprehensive approach has elucidated the role of neurons in PDAC, melanoma, pancreatitis, and metastasis, leveraging innovative tools for studying the molecular programs of CANs at the single-cell level. These insights not only unveil novel mechanisms orchestrated by neuronal activity but also pave the way for imminent clinical trials, aiming to combat PDAC by targeting cancer-associated neurons.
- MRTX1133 / BMS, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Pancreatic cancer organoids from the Human Cancer Models Initiative biobank reflect disease genotypes, capture patient heterogeneity, and are amenable to therapeutic screening (Section 11) - Mar 5, 2024 - Abstract #AACR2024AACR_7363;
Chemotherapeutics like Cisplatin were broadly cytotoxic while MRTX1133 exhibited greater toxicity in models with KRAS G12D variants as compared with KRAS wild type. Patient-derived cancer organoids from the HCMI recapitulate genotypes seen in patient populations and respond to therapeutic treatment in vitro.
- IMM-1-104 / Immuneering
Activity of IMM-1-104 alone or in combination with chemotherapy in RAS-altered pancreatic cancer models (Section 9) - Mar 5, 2024 - Abstract #AACR2024AACR_7353;
P1/2
The Phase 2a portion of the ongoing IMM-1-104 clinical study includes five arms, three of which focus on patients with pancreatic cancer, where IMM-1-104 will be evaluated as both monotherapy and in select combinations with approved chemotherapeutic agents. The new in vitro, in vivo and ML modeling data presented here further support an advancing translational roadmap for IMM-1-104 in pancreatic cancer.
- 5-fluorouracil / Generic mfg.
Monitoring early chemotherapy response in murine pancreatic ductal adenocarcinoma using non-invasive hyperpolarized magnetic resonance spectroscopic imaging with 13C-pyruvate (Section 8) - Mar 5, 2024 - Abstract #AACR2024AACR_7292;
We have applied a non-invasive approach for detection of metabolic changes under chemotherapy in murine PDAC. These findings will contribute in the long term to the establishment of predictive imaging biomarkers for PDAC.
- elraglusib (9-ING-41) / Actuate Therap
Genome wide CRISPR/Cas9 library screening identifies aurora kinase A as a regulator of elraglusib sensitivity in pancreatic cancer (Section 27) - Mar 5, 2024 - Abstract #AACR2024AACR_6797;
Strikingly, the AURKA inhibitor, alisertib, works synergistically with elraglusib to inhibit PDAC cell line growth and induce apoptosis. In summary, our results demonstrate that targeting AURKA is an effective approach to sensitize PDAC tumors to elraglusib.